An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.

Tissue factor (TF) is aberrantly expressed in solid cancers and is thought to contribute to disease progression through its procoagulant activity and its capacity to induce intracellular signaling in complex with factor VIIa (FVIIa). To explore the possibility of using tissue factor as a target for an antibody-drug conjugate (ADC), a panel of human tissue factor-specific antibodies (TF HuMab) was generated. Three tissue factor HuMab, that induced efficient inhibition of TF:FVIIa-dependent intracellular signaling, antibody-dependent cell-mediated cytotoxicity, and rapid target internalization, but had minimal impact on tissue factor procoagulant activity in vitro, were conjugated with the cytotoxic agents monomethyl auristatin E (MMAE) or monomethyl auristatin F (MMAF). Tissue factor-specific ADCs showed potent cytotoxicity in vitro and in vivo, which was dependent on tissue factor expression. TF-011-MMAE (HuMax-TF-ADC) was the most potent ADC, and the dominant mechanism of action in vivo was auristatin-mediated tumor cell killing. Importantly, TF-011-MMAE showed excellent antitumor activity in patient-derived xenograft (PDX) models with variable levels of tissue factor expression, derived from seven different solid cancers. Complete tumor regression was observed in all PDX models, including models that showed tissue factor expression in only 25% to 50% of the tumor cells. In conclusion, TF-011-MMAE is a promising novel antitumor agent with potent activity in xenograft models that represent the heterogeneity of human tumors, including heterogeneous target expression.

[1]  Aik Choon Tan,et al.  Patient-derived tumour xenografts as models for oncology drug development , 2012, Nature Reviews Clinical Oncology.

[2]  T. Drake,et al.  Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. , 1989, The American journal of pathology.

[3]  G. Adams,et al.  Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. , 2011, Cancer research.

[4]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[5]  A. Meye,et al.  Tissue factor and tumor: clinical and laboratory aspects. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[6]  C. Barbas,et al.  Protection against HIV‐1 infection in hu‐PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4‐binding site , 1995, AIDS.

[7]  K. Mann,et al.  Intracellular and Surface Distribution of Monocyte Tissue Factor: Application to Intersubject Variability , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[8]  M. Sliwkowski,et al.  Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer , 2011, Breast Cancer Research and Treatment.

[9]  G. Warnes,et al.  The Importance of Platelets in the Expression of Monocyte Tissue Factor Antigen Measured by a New Whole Blood Flow Cytometric Assay , 1996, Thrombosis and Haemostasis.

[10]  U. Pendurthi,et al.  Cellular localization and trafficking of tissue factor , 2006 .

[11]  A. K. Vine.  RECENT ADVANCES IN HAEMOSTASIS AND THROMBOSIS , 2009, Retina.

[12]  Damon L. Meyer,et al.  Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. , 2006, Bioconjugate chemistry.

[13]  P. Parren,et al.  Epidermal Growth Factor Receptor (EGFR) Antibody-Induced Antibody-Dependent Cellular Cytotoxicity Plays a Prominent Role in Inhibiting Tumorigenesis, Even of Tumor Cells Insensitive to EGFR Signaling Inhibition , 2011, The Journal of Immunology.

[14]  G. Escolar,et al.  Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia. , 2004, Blood.

[15]  U. Pendurthi,et al.  Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. , 2004, Blood.

[16]  D. Benjamin,et al.  Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate , 2010, Clinical Cancer Research.

[17]  P. Carmeliet,et al.  Low levels of tissue factor are compatible with development and hemostasis in mice. , 1998, The Journal of clinical investigation.

[18]  S. Shirasawa,et al.  Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. , 2005, Blood.

[19]  Hisataka Kobayashi,et al.  Fluorophore-quencher based activatable targeted optical probes for detecting in vivo cancer metastases. , 2009, Molecular pharmaceutics.

[20]  Y. Takada,et al.  Hemostasis, Thrombosis, and Vascular Biology: Inhibition of tissue factor signaling suppresses tumor growth , 2014 .

[21]  V. Seifert,et al.  Inhibition of tissue factor/protease-activated receptor-2 signaling limits proliferation, migration and invasion of malignant glioma cells , 2010, Neuroscience.

[22]  A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer , 2011, Molecular Cancer Therapeutics.

[23]  P. Parren,et al.  Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. , 2006, Cancer research.

[24]  E. Beltrami,et al.  Positive feedbacks of coagulation: their role in threshold regulation. , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[25]  Damon L. Meyer,et al.  Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate , 2004, Clinical Cancer Research.

[26]  K. Aldape,et al.  A model of molecular interactions on short oligonucleotide microarrays , 2003, Nature Biotechnology.

[27]  P. Parren,et al.  Dual Mode of Action of a Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer Therapy , 2004, The Journal of Immunology.

[28]  R. Kelley,et al.  Epitope Location on Tissue Factor Determines the Anticoagulant Potency of Monoclonal Anti-tissue Factor Antibodies , 2000, Thrombosis and Haemostasis.

[29]  G. Bigsby,et al.  Blood clotting activation analysis for preoperative differentiation of benign versus malignant ovarian masses , 2013, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[30]  Michael J. Gramer,et al.  Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange , 2013, Proceedings of the National Academy of Sciences.

[31]  P. Senter,et al.  The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma , 2012, Nature Biotechnology.

[32]  N. Lonberg,et al.  High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice , 1996, Nature Biotechnology.

[33]  K. Picha,et al.  CNTO 859, a humanized anti‐tissue factor monoclonal antibody, is a potent inhibitor of breast cancer metastasis and tumor growth in xenograft models , 2007, International journal of cancer.

[34]  R K Jain,et al.  Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. , 1990, Cancer research.

[35]  N. Mackman,et al.  Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[36]  M. Belting,et al.  Regulation of tissue factor-induced signaling by endogenous and recombinant tissue factor pathway inhibitor 1. , 2005, Blood.